161 related articles for article (PubMed ID: 25320584)
1. Decreased levels of circulating sex hormones as a biomarker of lung cancer in male patients with solitary pulmonary nodules.
Gu T; Wen Z; Xu S; Hua H; Zhang Z; Wen T; Fu Z; Lv X
Afr Health Sci; 2014 Jun; 14(2):356-63. PubMed ID: 25320584
[TBL] [Abstract][Full Text] [Related]
2. [Value of Combined Detection of Cytokines and Tumor Markers in the
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
[TBL] [Abstract][Full Text] [Related]
3. The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer.
Zheng J; Ye X; Liu Y; Zhao Y; He M; Xiao H
BMC Cancer; 2020 Feb; 20(1):106. PubMed ID: 32041568
[TBL] [Abstract][Full Text] [Related]
4. Decreased levels of sex hormones in females with solitary pulmonary nodules were risk factors for malignancy.
Wendan W; Mengyu L; Qiufeng Z
J Cardiothorac Surg; 2024 Mar; 19(1):119. PubMed ID: 38475837
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers.
Shen J; Liu Z; Todd NW; Zhang H; Liao J; Yu L; Guarnera MA; Li R; Cai L; Zhan M; Jiang F
BMC Cancer; 2011 Aug; 11():374. PubMed ID: 21864403
[TBL] [Abstract][Full Text] [Related]
6. The value of macrophage inhibitory cytokine-1 level in differentiating benign from malignant solitary pulmonary nodules.
Xu CH; Xue JS; Zhang XW; Yu LK; Lin Y
Clin Respir J; 2018 Apr; 12(4):1473-1478. PubMed ID: 28834599
[TBL] [Abstract][Full Text] [Related]
7. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
Li X; Zhang Q; Jin X; Cao L
World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
[TBL] [Abstract][Full Text] [Related]
8. Significance of plasma hepatocyte growth factor in diagnosis of benign and malignant solitary pulmonary nodules.
Yu H; Wang Y; Yu Q; Zhang H; Ma W; Shang S; Wang D
Int J Clin Exp Pathol; 2015; 8(2):2063-7. PubMed ID: 25973105
[TBL] [Abstract][Full Text] [Related]
9. Dynamic enhancement patterns of solitary pulmonary nodules at multi-detector row CT and correlation with vascular endothelial growth factor and microvessel density.
Jiang NC; Han P; Zhou CK; Zheng JL; Shi HS; Xiao J
Ai Zheng; 2009 Feb; 28(2):164-9. PubMed ID: 19550130
[TBL] [Abstract][Full Text] [Related]
10. Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Kupert E; Anderson M; Liu Y; Succop P; Levin L; Wang J; Wikenheiser-brokamp K; Chen P; Pinney SM; Macdonald T; Dong Z; Starnes S; Lu S
BMC Cancer; 2011 Dec; 11():513. PubMed ID: 22151235
[TBL] [Abstract][Full Text] [Related]
11. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules.
Xing L; Su J; Guarnera MA; Zhang H; Cai L; Zhou R; Stass SA; Jiang F
Clin Cancer Res; 2015 Jan; 21(2):484-9. PubMed ID: 25593345
[TBL] [Abstract][Full Text] [Related]
12. Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules.
Xie J; Ruan Z; Zheng J; Gong Y; Wang Y; Hu B; Cheng J; Huang Q
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2681-2692. PubMed ID: 34791530
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma.
Ding C; Zhou X; Xu C; Chen J; Ju S; Chen T; Liang Z; Cui Z; Li C; Zhao J
Thorac Cancer; 2018 Nov; 9(11):1413-1420. PubMed ID: 30178907
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of malignant and benign pulmonary nodules with first-pass dual-input perfusion CT.
Yuan X; Zhang J; Quan C; Cao J; Ao G; Tian Y; Li H
Eur Radiol; 2013 Sep; 23(9):2469-74. PubMed ID: 23793548
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the discriminative methods for diagnosis of benign and malignant solitary pulmonary nodules based on serum markers.
Wang W; Liu M; Wang J; Tian R; Dong J; Liu Q; Zhao X; Wang Y
Oncol Res Treat; 2014; 37(12):740-6. PubMed ID: 25531720
[TBL] [Abstract][Full Text] [Related]
17. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.
Fahrmann JF; Grapov D; DeFelice BC; Taylor S; Kim K; Kelly K; Wikoff WR; Pass H; Rom WN; Fiehn O; Miyamoto S
Cancer Biomark; 2016 Mar; 16(4):609-17. PubMed ID: 27002763
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
19. Establishment and validation of a prediction model for the probability of malignancy in solid solitary pulmonary nodules in northwest China.
Duan XQ; Wang XL; Zhang LF; Liu XZ; Zhang WW; Liu YH; Dong CH; Zhao XH; Chen L
J Surg Oncol; 2021 Mar; 123(4):1134-1143. PubMed ID: 33497476
[TBL] [Abstract][Full Text] [Related]
20. Clinical-radiological predictive model in differential diagnosis of small (≤ 20 mm) solitary pulmonary nodules.
Zhao HC; Xu QS; Shi YB; Ma XJ
BMC Pulm Med; 2021 Sep; 21(1):281. PubMed ID: 34482833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
